Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Long-Term Deferred Tax (2019 - 2025)

Maxcyte (MXCT) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $945000.0 as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 38.11% to $945000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $945000.0 through Dec 2025, down 38.11% year-over-year, with the annual reading at $945000.0 for FY2025, 38.11% down from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $945000.0 at Maxcyte, down from $1.5 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $1.5 million in Q4 2024, with the low at $945000.0 in Q4 2025.